To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
The AGM held on May 24, 2022 approved two long-term incentive programs (“LTI2022”), one for Management and leading employees and one for board members.LTI2022 for Management and leading…
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue has now been registered with the Danish Companies Registration Office. The Company hereby announces that the last day of trading in paid subscribed shares (Sw. BTA) will be on 21 July 2022 and stop day will be on 25 July 2022.
Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today issued new shares in connection with the capital increase directed at Annika Espander, the Company´s strategic advisor.
Initiator Pharma A/S (“Initiator Pharma” or the “Company”) today announces the outcome of the rights issue, for which the subscription period ended on 30 June 2022 (the “Rights Issue”). The outcome shows that 2,264,182 shares, corresponding to approximately 41.4 percent of the Rights Issue, were subscribed for with support of subscription rights (incl. pre-subscription commitments). In addition, subscription of 44,683 shares without support of subscription rights, corresponding to approximately 0.9 percent of the Rights Issue, have been received. In total, the subscription (incl. pre-subscription commitments) amounts to approximately 42.3 percent of the Rights Issue. Hence, underwriting commitments of 3,154,561 shares, corresponding to approximately 57.7 percent of the Rights Issue, will be utilized. Initiator Pharma will be provided approximately SEK 41 million before deduction of transaction related costs. Settlement notes are expected to be sent out today, 5 July 2022.
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today resolved to carry out a directed share issue to a financial advisor in connection with the recently completed rights issue.
Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2021
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a buyback of shares in order to sell shares to the board of directors under the LTI2021-program.
Today, 16 June 2022, is the first day of the subscription period in Initiator Pharma A/S’s (“Initiator Pharma” or “the Company”) share issue, with preferential rights for existing shareholders (the “Rights Issue”). The public is also invited to subscribe for shares in the Rights Issue. The subscription period runs until, and including, 30 June 2022. The Rights Issue is fully secured through subscription and underwriting commitments and will provide the Company with approximately SEK 41 million before deduction of transaction related costs. The prospectus and a summary teaser are available on the websites of the Company (www.initiatorpharma.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Subscription forms can be obtained from Nordic Issuing AB’s website. In addition, it is possible to subscribe for shares digitally through Nordic Issuing AB’s website.